Active, not recruitingNCT05608291ClinicalTrials.gov record

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Melanoma

Ask WCR about this study Official registry record ↗

THE QUICK READ

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type: Interventional
Phase: Phase 3
Age range: 12 years - Not specified
Sex eligible: All sexes
Healthy volunteers: Not accepted
Participants: 1564 Actual

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab.

The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting.

The study is looking at several other research questions, including:

What side effects may happen from receiving the study drugs.
How much study drug is in the blood at different times.
Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections.
How administering the study drugs might improve quality of life.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Key Inclusion Criteria:

1. All patients must be either stage IIB, IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that is completely surgically resected in order to be eligible as defined by the protocol
2. Complete surgical resection must be performed within 12 weeks prior to randomization, and enrollment may occur only after satisfactory wound healing from the surgery
3. All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization, as described in the protocol

Key Exclusion Criteria:

1. Uveal melanoma
2. Any evidence of residual disease after surgery by imaging, pathology, or cytology.
3. Ongoing or recent (within 2 years) evidence of clinically significant autoimmune disease that required treatment
4. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection, as described in the protocol
5. Another malignancy that is currently progressing or that required active treatment in the past 5 years, as described in the protocol
6. Participants with a history of myocarditis
7. Adolescent patients (≥12 to \<18 years old) with body weight \<40 kg

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment: Random assignment
Masking: Quadruple masked

Fianlimab HD + Cemiplimab

Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab

Drug: Fianlimab · Drug: Cemiplimab

Fianlimab LD + Cemiplimab

Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab

Drug: Fianlimab · Drug: Cemiplimab

Pembrolizumab

Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo

Drug: Pembrolizumab · Drug: Placebo

Fianlimab DRUG

Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks

Cemiplimab DRUG

Cemiplimab will be administered by IV infusion Q 3 weeks

Pembrolizumab DRUG

Pembrolizumab will be administered by IV infusion Q 3 weeks

Placebo DRUG

Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks

Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Relapse free survival (RSF)

Time frame: Up to 5 Years

Time from randomization to the first documented recurrence of disease at any site (excluding new primary melanomas) or death from any cause, whichever occurs first.

Secondary measures

Distant metastasis-free survival (DMFS)

Time frame: Up to 5 Years

Time between the date of randomization and the date of the first distant metastasis.

Overall survival (OS)

Time frame: Up to 5 Years

Time from randomization to the date of death.

Occurrence of treatment-emergent adverse events (TEAEs)

Time frame: Up to 5 Years

A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

Occurrence of immune-mediated EAEs (im-EAEs)

Time frame: Up to 5 Years

imAEs are a unique set of toxicities thought to be caused by unrestrained cellular immune responses.

Occurrence of serious adverse events (SAEs)

Time frame: Up to 5 Years

An SAE is any untoward medical occurrence that at any dose:

Results in death - includes all deaths, even those that appear to be completely unrelated to study drug (eg, a car accident in which a patient is a passenger).
Is life-threatening
Requires in-patient hospitalization or prolongation of existing hospitalization.
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect.
Is an important medical event

Occurrence of adverse events of special interest (AESIs)

Time frame: Up to 5 Years

An AESI (serious or non-serious) is one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the sponsor can be appropriate. Such an event might warrant further investigation in order to characterize and understand it

Occurrence of TEAEs resulting in death

Time frame: Up to 5 Years

A TEAE resulting in death is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

Occurrence of dose-limiting toxicity (DLT)

Time frame: Up to 5 Years

A DLT is defined as a study-drug related TEAE, including imAEs, that could preclude enrolling additional adolescent patients at the selected dose. Dose-limiting toxicity will be evaluated in adolescents only.

Occurrence of interruption or discontinuation of study drug(s) due to TEAE

Time frame: Up to 5 Years

Occurrence of laboratory abnormalities

Time frame: Up to 5 Years

As assessed by the NCI-CTCAE grading system (≥ Grade 3 or higher)

Concentrations of fianlimab in serum over time

Time frame: Up to 5 Years

The concentrations of fianlimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.

Concentrations of cemiplimab in serum over time

Time frame: Up to 5 Years

The concentrations of cemiplimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.

Concentration of finalimab anti-drug antibodies (ADA) and neutralizing antibodies

Time frame: Up to 5 Years

Immunogenicity will be characterized per drug molecule by ADA and NAb status.

Concentration of cemiplimab anti-drug antibodies (ADA) and neutralizing antibodies

Time frame: Up to 5 Years

Immunogenicity will be characterized per drug molecule by ADA and NAb status.

Patient report outcomes (PRO) for adults as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)

Time frame: Up to 5 Year

The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.

The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. More points are considered to have a better outcome.

PRO for adults as measured by the European Quality of Life Dimension 5 (EQ-5D-5L)

Time frame: Up to 5 Years

The EQ-5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

PRO for adults as measured by the Functional Assessment of Cancer Therapy (FACT) - melanoma

Time frame: Up to 5 Years

The FACT-M is a melanoma-specific quality of life questionnaire that is composed of items from the Functional Assessment of Cancer Therapy-General (FACT-G). The FACT-M is scored on a 5 point Likert-scale: "Not at all", "A little bit", "Somewhat", "Quite a bit", and "Very much.". A Higher score represents higher Health Related Quality of Life (HRQoL).

PRO for adults as determined by the Patient Global Impressions Scale (PGIS)

Time frame: Up to 5 Years

The PGIS is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time by using a 4-point Likert scale that ranges from (1) = "none (no symptoms)" to (4) = "severe".

PRO for adults as determined by the Patient Global Impressions of Change Scale (PGIC)

Time frame: Up to 5 Years

The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 5-point Likert scale anchored by (1) "much better" to (5) "much worse", with (4) = "no change".

Time to global health status/quality of life deterioration per EORTC QLQ-C30

Time frame: Up to 5 years

Not reported in this registry record.

Time to physical functioning deterioration per EORTC QLQ-C30

Time frame: Up to 5 Years

Not reported in this registry record.

Time to role functioning deterioration per EORTC QLQ-C30

Time frame: Up to 5 Years

Not reported in this registry record.

No results are flagged as posted.

Review the complete result tables and limitations in the official record.

Open official results ↗

Research locations (211)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

Find a location in this study

211 locations

UC San DiegoLa Jolla, California, United StatesStatus unknown

What this study involves

About the research

Who may be able to participate?

Treatment, groups and participation

What researchers are measuring

Primary measures

Secondary measures

Research locations (211)

Study team and timeline

Official study contacts

Ask Wellness Clinical Research